Ask AI
Lung Cancer Discoveries From ASCO 2025

CE / CME

Bridging Lung Cancer Discoveries to Practice—CCO’s Independent Conference Highlights From the 2025 ASCO Annual Meeting

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: July 08, 2025

Expiration: January 07, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In consultation with a patient with previously untreated ES-SCLC without CNS disease, which of the following results would you tell him/her was reported from the phase III IMforte trial of lurbinectedin + atezolizumab vs atezolizumab as first-line maintenance therapy after platinum etoposide plus atezolizumab?

2.

The phase III NeoADAURA study evaluated preoperative treatment with osimertinib (Osi) ± chemotherapy (CT) vs CT alone in patients with resectable stage II-IIIB EGFR mutant NSCLC. Which of the following results were shown for the osimertinib containing arms vs CT plus placebo arm regarding major pathologic response (MPR)?

3.

Which of the following patient subgroups with documented locally advanced or metastatic EGFR ex20ins–mutated NSCLC and prior treatment for recurrent/metastatic disease (including amivantamab) may potentially benefit from zipalertinib according to the primary results from the phase IIb REZILIENT1 trial results presented at ASCO 2025?